# Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD).

> **NCT07476872** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 33 (estimated)

## Conditions studied

- cGVHD
- HSCT

## Interventions

- **DRUG:** Gecacitinib

## Key facts

- **NCT ID:** NCT07476872
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-16
- **Primary completion:** 2027-11-01
- **Final completion:** 2028-11-01
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07476872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07476872, "Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD).". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07476872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*